研究目的
To examine the potential of a radiolabeled dendritic galactose carbohydrate (18F-labeled galactodendritic unit 4) in imaging urothelial malignancies, specifically galectin-1 overexpressing bladder cancer.
研究成果
The 18F-labeled galactodendritic unit 4 demonstrated high potential as a diagnostic tool for imaging galectin-1 overexpressing bladder cancer, with specific accumulation in tumors and minimal accumulation in non-tumor tissues.
研究不足
The study did not determine the nonspecific binding of the galactose radiotracer in vivo using a bladder cancer cell line with low levels of galectin-1. Further studies are needed to explore the radiotracer's ability to bind to other galactose-binding proteins overexpressed in bladder cancer.
1：Experimental Design and Method Selection
The study involved the synthesis of a 18F-labeled galactodendritic unit from its tosylate precursor, followed by in vivo studies in a galectin-expressing UMUC3 orthotopic bladder cancer model to evaluate its imaging potential.
2：Sample Selection and Data Sources
Human bladder cancer cells UMUC3, HT1197, T24, UMUC14, and RT112 were used, cultured according to ATCC, Sigma-Aldrich, or ECACC recommendations.
3：List of Experimental Equipment and Materials
Equipment included a Shimadzu UFLC HPLC system, Waters instrument with SQD detector for LC-MS, Bruker AV 500 MHz for NMR, and a Vevo 2100 Imaging System for ultrasound imaging. Materials included various chemicals and solvents from Sigma-Aldrich.
4：Experimental Procedures and Operational Workflow
The synthesis involved multiple steps including nucleophilic substitution, tosylation, and fluorination. In vivo studies included intravesical administration of the radiotracer and PET/CT imaging.
5：Data Analysis Methods
Data analysis involved fluorescence-quenching assays, gamma counting for radioactivity measurement, and PET image analysis using AMIDE software.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
